TXN-A

TXN-A is a first-in-class, orally bioavailable, and highly selective small molecule degrader of Unc-51 like autophagy activating kinase 1 (ULK1). It operates via a Cereblon (CRBN)-dependent ubiquitin-proteasome system pathway to induce the degradation of ULK1 protein. By targeting ULK1, TXN-A effectively suppresses autophagy, a survival mechanism often exploited by triple-negative breast cancer (TNBC) cells to resist chemotherapy. Preclinical studies demonstrate that TXN-A exhibits strong synergistic anti-tumor activity when combined with taxanes like paclitaxel, significantly inhibiting tumor growth in xenograft models.